- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01312402
Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome
June 24, 2014 updated by: Richard W. Hertle, Akron Children's Hospital
This study is a prospective, single crossover, double-masked, controlled clinical trial that will use topical brinzolamide (Azopt)ophthalmic medication to try to improve the nystagmus and visual consequences of nystagmus in patients with infantile nystagmus syndrome (INS).
Subjects will undergo a clinical exam, questionnaire and eye movement recordings on day 1 and then receive either topical Azopt or placebo three times a day in both eyes for days 2,3 and 4 followed on the morning of day 5 by a repeat clinical exam, questionnaire and eye movement recordings.
After at least one week, this protocol is repeated with the crossover regimen being taken by the subject.
One week after all medications are discontinued, another clinical exam is done before study discharge.
The hypothesis is that nystagmus and associated visual symptoms will be improved while on the Azopt compared to the placebo.
There will be a total of 5 visits over a 1-2 month period.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
5 subjects are expected to be enrolled in the study. Each subject will be in the study for approximately 1 month.
Efficacy will be assessed by:
- ETDRS Visual Acuity Testing of Binocular Best Corrected Visual Acuity In The Nystagmus Null Zone
- The Validated Amblyopia & Strabismus Ocular Motor Questionnaire
- Eye Movement Recording Data Analysis of The Nystagmus Waveform
Safety will be evaluated by:
- Ocular signs and symptoms
- Visual acuity (uncorrected and best corrected)
- Slit lamp exam and Intraocular Pressure
- Systemic signs and symptoms
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Akron, Ohio, United States, 44308
- Akron Children's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
12 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age; greater than 12 years old and able to cooperate for full study protocol
- Subject able to understand and sign informed consent
- Subject able to participate in complete ophthalmic and ocular motility evaluation
- Subjects with Infantile Nystagmus Syndrome diagnosed by clinical evaluation and eye movement recordings
- Best-binocular visual acuity in null position 20/50 to 20/200 inclusive using ATS or ETDRS vision testing
- Subject/family able and willing to make the required study visits
- No previous ophthalmic treatment for nystagmus other than for refractive error
Exclusion Criteria:
- Any current use of systemic or topical medications (traditional or non-traditional)
- History of ocular surgery, trauma or chronic ocular disease other than amblyopia
- Systemic diseases requiring medication or other treatments that are known to affect the ocular motor system (e.g., depression, seizure disorders, psychosis)
- Behavioral or neurological disorders which interfere with the study
- Physical or mental impairment precluding study compliance
- Participation in any study involving an IND investigational drug within the past year
- Individual (female) is pregnant, nursing or planning a pregnancy (The safety of Azopt for use during pregnancy has NOT been determined.)
- Periodicity or aperiodicity of INS present on eye movement recordings
- Allergy to sulfa or other components of Azopt solution
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Topical Brinzolamide (Azopt)
ophthalmic drop given three times a day
|
1 drop three times a day in both eyes on days 2,3 and 4
Other Names:
|
Placebo Comparator: placebo ophthalmic drop in 5 mL solution
masked non-active eye drop (absence of Brinzolamide)
|
Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Corrected Binocular Visual Acuity
Time Frame: 1 week
|
Early Treatment of Diabetic Retinopathy Study Vision Testing Protocol of Best corrected Binocular Acuity
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Function
Time Frame: 5 Days
|
THe Validated Amblyopia and Visual Function Questionnaire will be administered
|
5 Days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Richard W. Hertle, M.D., Akron Children's Hospital
- Principal Investigator: Dongsheng Yang, Ph.D., Akron Children's Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Dell'Osso LF, Jacobs JB. An expanded nystagmus acuity function: intra- and intersubject prediction of best-corrected visual acuity. Doc Ophthalmol. 2002 May;104(3):249-76. doi: 10.1023/a:1015299930849.
- Hertle RW, Dell'Osso LF, FitzGibbon EJ, Thompson D, Yang D, Mellow SD. Horizontal rectus tenotomy in patients with congenital nystagmus: results in 10 adults. Ophthalmology. 2003 Nov;110(11):2097-105. doi: 10.1016/S0161-6420(03)00802-9.
- Hertle RW, Anninger W, Yang D, Shatnawi R, Hill VM. Effects of extraocular muscle surgery on 15 patients with oculo-cutaneous albinism (OCA) and infantile nystagmus syndrome (INS). Am J Ophthalmol. 2004 Dec;138(6):978-87. doi: 10.1016/j.ajo.2004.07.029.
- Hertle RW, Dell'Osso LF, FitzGibbon EJ, Yang D, Mellow SD. Horizontal rectus muscle tenotomy in children with infantile nystagmus syndrome: a pilot study. J AAPOS. 2004 Dec;8(6):539-48. doi: 10.1016/j.jaapos.2004.08.005.
- Jacobs JB, Dell'Osso LF, Hertle RW, Acland GM, Bennett J. Eye movement recordings as an effectiveness indicator of gene therapy in RPE65-deficient canines: implications for the ocular motor system. Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2865-75. doi: 10.1167/iovs.05-1233.
- Jacobs JB, Dell'Osso LF, Wang ZI, Acland GM, Bennett J. Using the NAFX to measure the effectiveness over time of gene therapy in canine LCA. Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4685-92. doi: 10.1167/iovs.09-3387. Epub 2009 May 20.
- Hertle RW, Yang D, Adkinson T, Reed M. Topical brinzolamide (Azopt) versus placebo in the treatment of infantile nystagmus syndrome (INS). Br J Ophthalmol. 2015 Apr;99(4):471-6. doi: 10.1136/bjophthalmol-2014-305915. Epub 2014 Oct 21.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (Actual)
March 1, 2014
Study Completion (Actual)
March 1, 2014
Study Registration Dates
First Submitted
January 21, 2011
First Submitted That Met QC Criteria
March 9, 2011
First Posted (Estimate)
March 10, 2011
Study Record Updates
Last Update Posted (Estimate)
June 25, 2014
Last Update Submitted That Met QC Criteria
June 24, 2014
Last Verified
June 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 101109
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infantile Nystagmus Syndrome
-
Zagazig UniversityActive, not recruiting
-
Merz Pharmaceuticals GmbHCompletedNystagmus, Acquired | Nystagmus, Congenital IdiopathicUnited Kingdom
-
Aalborg University HospitalCompletedHealthy Volunteers | Positional NystagmusDenmark
-
Julie DawsonMedical Research Council; University of East AngliaCompletedOptokinetic NystagmusUnited Kingdom
-
National Eye Institute (NEI)Completed
-
Quesada, Rocío VicoNot yet recruitingVestibular Function Tests | Nystagmus Vestibular
-
University of BaselCompletedVisual AcuitySwitzerland
-
Boston Children's HospitalNational Eye Institute (NEI)RecruitingStrabismus | Nystagmus, CongenitalUnited States
-
National Eye Institute (NEI)Completed
-
Case Western Reserve UniversityCompletedNystagmusUnited States
Clinical Trials on topical brinzolamide 1% in 5mL ophthalmic medication
-
Alcon ResearchCompleted
-
Padagis LLCCompletedOcular Hypertension | Glaucoma, Open-AngleUnited States
-
Bausch & Lomb IncorporatedCompletedGlaucoma | Open Angle or Ocular HypertensionUnited States
-
Bausch & Lomb IncorporatedCompletedGlaucoma | Open Angle or Ocular HypertensionUnited States
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle Glaucoma
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle Glaucoma
-
Alcon ResearchTerminatedOcular Hypertension | Open-Angle Glaucoma
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle Glaucoma
-
Alcon ResearchCompletedOcular Hypertension | Open-Angle Glaucoma